Patrick O'Brien Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 2 months, 1 week ago
Patrick O'Brien has an estimated net worth of at least $25.5 million*, as of Oct. 29, 2025. They own 547,408 shares of ARWR stock. They have sold 184,867 shares of ARWR stock since 2021, for an estimated $5.1 million.
Patrick O'Brien $ARWR SEC Form 4 Insider Trading
Patrick O'Brien has filed a total of 38 insider trades in $ARWR since 2021. Their most recent trade was a sale of 46 shares, made on Jan 05, 2026. Their largest trade was a sale of 19,658 shares, made on Jan 06, 2025. We estimate that they now own 547,408 shares of $ARWR, worth an estimated $20.4 million.
Insider Trading at $ARWR
There have been a total of 215 insider trades reported at $ARWR since 2021, with 3,655 shares purchased and 2.1 million shares sold. The most active insider traders in $ARWR stock have been Christopher Richard Anzalone, Patrick O'Brien, and Kenneth Allen Myszkowski. The most recent trade was a sale of 2,700 shares reported by Patrick O'Brien (COO), made on Jan 05, 2026.
History of Insider Stock Trades by Patrick O'Brien
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
ARWR
|
Sale | 46 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 900 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 5,873 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 2,336 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 4,368 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 6,164 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 13,451 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 11,842 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 2,700 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 900 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 313 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 600 | Jan 05, 2026 | Jan. 5, 2026, 10:50 p.m. |
ARWR
|
Sale | 9,526 | Jan 06, 2025 | Jan. 7, 2025, 10:28 p.m. |
ARWR
|
Sale | 8,000 | Jan 07, 2025 | Jan. 7, 2025, 10:28 p.m. |
ARWR
|
Sale | 19,658 | Jan 06, 2025 | Jan. 7, 2025, 10:28 p.m. |
ARWR
|
Sale | 12,741 | Jan 05, 2024 | Jan. 5, 2024, 8:58 p.m. |
ARWR
|
Sale | 3,849 | Jan 03, 2024 | Jan. 5, 2024, 8:58 p.m. |
ARWR
|
Sale | 2,800 | Jan 03, 2024 | Jan. 5, 2024, 8:58 p.m. |
ARWR
|
Sale | 400 | Jan 03, 2024 | Jan. 5, 2024, 8:58 p.m. |
ARWR
|
Sale | 1,700 | Jan 03, 2024 | Jan. 5, 2024, 8:58 p.m. |
ARWR
|
Sale | 1,600 | Jan 04, 2024 | Jan. 5, 2024, 8:58 p.m. |
ARWR
|
Sale | 1,900 | Jan 05, 2024 | Jan. 5, 2024, 8:58 p.m. |
ARWR
|
Sale | 8,200 | Jan 05, 2024 | Jan. 5, 2024, 8:58 p.m. |
ARWR
|
Sale | 7,500 | Jan 05, 2023 | Jan. 6, 2023, 8:30 p.m. |
ARWR
|
Sale | 7,500 | Jan 05, 2023 | Jan. 6, 2023, 8:30 p.m. |
ARWR
|
Sale | 5,286 | Jan 03, 2023 | Jan. 5, 2023, 8:10 p.m. |
ARWR
|
Sale | 300 | Jan 03, 2023 | Jan. 5, 2023, 8:10 p.m. |
ARWR
|
Sale | 270 | Jan 03, 2023 | Jan. 5, 2023, 8:10 p.m. |
ARWR
|
Sale | 70 | Jan 03, 2023 | Jan. 5, 2023, 8:10 p.m. |
ARWR
|
Sale | 2,894 | Jan 03, 2023 | Jan. 5, 2023, 8:10 p.m. |
ARWR
|
Sale | 2,653 | Jan 03, 2023 | Jan. 5, 2023, 8:10 p.m. |
ARWR
|
Sale | 5,527 | Jan 03, 2023 | Jan. 5, 2023, 8:10 p.m. |
ARWR
|
Sale | 500 | Jan 03, 2023 | Jan. 5, 2023, 8:10 p.m. |
ARWR
|
Sale | 4,400 | Jan 05, 2022 | Jan. 6, 2022, 8 p.m. |
ARWR
|
Sale | 316 | Jan 05, 2022 | Jan. 6, 2022, 8 p.m. |
ARWR
|
Sale | 12,434 | Jan 05, 2022 | Jan. 6, 2022, 8 p.m. |
ARWR
|
Sale | 10,350 | Jan 05, 2022 | Jan. 6, 2022, 8 p.m. |
ARWR
|
Sale | 5,000 | Jan 05, 2022 | Jan. 6, 2022, 8 p.m. |
$ARWR Executives and Stock Owners with Insider Trades
-
Christopher Richard Anzalone, Chief Executive Officer
-
Patrick O'Brien, COO and General Counsel
-
Kenneth Allen Myszkowski, Chief Financial Officer
-
James C Hamilton, Chief Medical Officer
-
Patrick O'Brien, COO
-
Martin Javier San, Chief Medical Officer
-
James C Hamilton, Chief Discovery/Trans Medicine
-
Patrick O'Brien, General Counsel
-
Tracie Oliver, Chief Commercial Officer
-
James Hassard, Chief Commercial Officer
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.